PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 000466

CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine

Identifieur interne : 000466 ( PascalFrancis/Curation ); précédent : 000465; suivant : 000467

CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine

Auteurs : Dubravka Grdic Eliasson [Suède] ; Karim El Bakkouri [Belgique] ; Karin Schön [Suède] ; Anna Ramne [Suède] ; Els Festjens [Belgique] ; Bjdrn Löwenadler [Suède] ; Walter Fiers [Belgique] ; Xavier Saelens [Belgique] ; Nils Lycke [Suède]

Source :

Vaccine [ 0264-410X ] ; 2008.

RBID : Pascal:08-0158301

Descripteurs français

Pascal (Inist)
- Virus grippal A, Muqueuse, Adjuvant immunologique, Vaccin, Vaccination, IgA, Immunomodulation, Rate, Ganglion lymphatique, Grippe, Antigène, Peptide, Déterminant antigénique.
Wicri :
- topic : Vaccin, Vaccination.

English descriptors

KwdEn :
- Antigen, Antigenic determinant, IgA, Immunological adjuvant, Immunomodulation, Influenza, Influenza A virus, Lymph node, Mucosa, Peptides, Spleen, Vaccination, Vaccine.

Abstract

At present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 26`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine`
A11	`01`	`1`		`@1 GRDIC ELIASSON (Dubravka)`
A11	`02`	`1`		`@1 EL BAKKOURI (Karim)`
A11	`03`	`1`		`@1 SCHÖN (Karin)`
A11	`04`	`1`		`@1 RAMNE (Anna)`
A11	`05`	`1`		`@1 FESTJENS (Els)`
A11	`06`	`1`		`@1 LÖWENADLER (Bjdrn)`
A11	`07`	`1`		`@1 FIERS (Walter)`
A11	`08`	`1`		`@1 SAELENS (Xavier)`
A11	`09`	`1`		`@1 LYCKE (Nils)`
A14	`01`			`@1 Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435 @2 40530 Götebors @3 SWE @Z 1 aut. @Z 3 aut. @Z 9 aut.`
A14	`02`			`@1 Department for Molecular Biomedical Research, VIB and University of Ghent @2 Ghent @3 BEL @Z 2 aut. @Z 5 aut. @Z 7 aut. @Z 8 aut.`
A14	`03`			`@1 Biovitrum AB @2 Götebory @3 SWE @Z 4 aut.`
A14	`04`			`@1 AstraZeneca @2 Götebors @3 SWE @Z 6 aut.`
A20				`@1 1243-1252`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000175098950120`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 63 ref.`
A47	`01`	`1`		`@0 08-0158301`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 At present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Muqueuse @5 05`
C03	`02`	`X`	`ENG`	`@0 Mucosa @5 05`
C03	`02`	`X`	`SPA`	`@0 Mucosa @5 05`
C03	`03`	`X`	`FRE`	`@0 Adjuvant immunologique @5 06`
C03	`03`	`X`	`ENG`	`@0 Immunological adjuvant @5 06`
C03	`03`	`X`	`SPA`	`@0 Coadyuvante inmunológico @5 06`
C03	`04`	`X`	`FRE`	`@0 Vaccin @5 07`
C03	`04`	`X`	`ENG`	`@0 Vaccine @5 07`
C03	`04`	`X`	`SPA`	`@0 Vacuna @5 07`
C03	`05`	`X`	`FRE`	`@0 Vaccination @5 08`
C03	`05`	`X`	`ENG`	`@0 Vaccination @5 08`
C03	`05`	`X`	`SPA`	`@0 Vacunación @5 08`
C03	`06`	`X`	`FRE`	`@0 IgA @5 09`
C03	`06`	`X`	`ENG`	`@0 IgA @5 09`
C03	`06`	`X`	`SPA`	`@0 IgA @5 09`
C03	`07`	`X`	`FRE`	`@0 Immunomodulation @5 10`
C03	`07`	`X`	`ENG`	`@0 Immunomodulation @5 10`
C03	`07`	`X`	`SPA`	`@0 Inmunomodulación @5 10`
C03	`08`	`X`	`FRE`	`@0 Rate @5 11`
C03	`08`	`X`	`ENG`	`@0 Spleen @5 11`
C03	`08`	`X`	`SPA`	`@0 Bazo @5 11`
C03	`09`	`X`	`FRE`	`@0 Ganglion lymphatique @5 12`
C03	`09`	`X`	`ENG`	`@0 Lymph node @5 12`
C03	`09`	`X`	`SPA`	`@0 Ganglio linfático @5 12`
C03	`10`	`X`	`FRE`	`@0 Grippe @5 14`
C03	`10`	`X`	`ENG`	`@0 Influenza @5 14`
C03	`10`	`X`	`SPA`	`@0 Gripe @5 14`
C03	`11`	`X`	`FRE`	`@0 Antigène @5 67`
C03	`11`	`X`	`ENG`	`@0 Antigen @5 67`
C03	`11`	`X`	`SPA`	`@0 Antígeno @5 67`
C03	`12`	`X`	`FRE`	`@0 Peptide @5 68`
C03	`12`	`X`	`ENG`	`@0 Peptides @5 68`
C03	`12`	`X`	`SPA`	`@0 Péptido @5 68`
C03	`13`	`X`	`FRE`	`@0 Déterminant antigénique @5 69`
C03	`13`	`X`	`ENG`	`@0 Antigenic determinant @5 69`
C03	`13`	`X`	`SPA`	`@0 Determinante antigénico @5 69`
C07	`01`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`01`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`02`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virose`
C07	`04`	`X`	`ENG`	`@0 Viral disease`
C07	`04`	`X`	`SPA`	`@0 Virosis`
C07	`05`	`X`	`FRE`	`@0 Infection`
C07	`05`	`X`	`ENG`	`@0 Infection`
C07	`05`	`X`	`SPA`	`@0 Infección`
N21				`@1 098`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A31

Links to Exploration step

Pascal:08-0158301

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine</title>
<author><name sortKey="Grdic Eliasson, Dubravka" sort="Grdic Eliasson, Dubravka" uniqKey="Grdic Eliasson D" first="Dubravka" last="Grdic Eliasson">Dubravka Grdic Eliasson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435</s1>
<s2>40530 Götebors</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="El Bakkouri, Karim" sort="El Bakkouri, Karim" uniqKey="El Bakkouri K" first="Karim" last="El Bakkouri">Karim El Bakkouri</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Schon, Karin" sort="Schon, Karin" uniqKey="Schon K" first="Karin" last="Schön">Karin Schön</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435</s1>
<s2>40530 Götebors</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Ramne, Anna" sort="Ramne, Anna" uniqKey="Ramne A" first="Anna" last="Ramne">Anna Ramne</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biovitrum AB</s1>
<s2>Götebory</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Festjens, Els" sort="Festjens, Els" uniqKey="Festjens E" first="Els" last="Festjens">Els Festjens</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Lowenadler, Bjdrn" sort="Lowenadler, Bjdrn" uniqKey="Lowenadler B" first="Bjdrn" last="Löwenadler">Bjdrn Löwenadler</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>AstraZeneca</s1>
<s2>Götebors</s2>
<s3>SWE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Fiers, Walter" sort="Fiers, Walter" uniqKey="Fiers W" first="Walter" last="Fiers">Walter Fiers</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Saelens, Xavier" sort="Saelens, Xavier" uniqKey="Saelens X" first="Xavier" last="Saelens">Xavier Saelens</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Lycke, Nils" sort="Lycke, Nils" uniqKey="Lycke N" first="Nils" last="Lycke">Nils Lycke</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435</s1>
<s2>40530 Götebors</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0158301</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0158301 INIST</idno>
<idno type="RBID">Pascal:08-0158301</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A31</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000466</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine</title>
<author><name sortKey="Grdic Eliasson, Dubravka" sort="Grdic Eliasson, Dubravka" uniqKey="Grdic Eliasson D" first="Dubravka" last="Grdic Eliasson">Dubravka Grdic Eliasson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435</s1>
<s2>40530 Götebors</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="El Bakkouri, Karim" sort="El Bakkouri, Karim" uniqKey="El Bakkouri K" first="Karim" last="El Bakkouri">Karim El Bakkouri</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Schon, Karin" sort="Schon, Karin" uniqKey="Schon K" first="Karin" last="Schön">Karin Schön</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435</s1>
<s2>40530 Götebors</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Ramne, Anna" sort="Ramne, Anna" uniqKey="Ramne A" first="Anna" last="Ramne">Anna Ramne</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Biovitrum AB</s1>
<s2>Götebory</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Festjens, Els" sort="Festjens, Els" uniqKey="Festjens E" first="Els" last="Festjens">Els Festjens</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Lowenadler, Bjdrn" sort="Lowenadler, Bjdrn" uniqKey="Lowenadler B" first="Bjdrn" last="Löwenadler">Bjdrn Löwenadler</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>AstraZeneca</s1>
<s2>Götebors</s2>
<s3>SWE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author><name sortKey="Fiers, Walter" sort="Fiers, Walter" uniqKey="Fiers W" first="Walter" last="Fiers">Walter Fiers</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Saelens, Xavier" sort="Saelens, Xavier" uniqKey="Saelens X" first="Xavier" last="Saelens">Xavier Saelens</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Lycke, Nils" sort="Lycke, Nils" uniqKey="Lycke N" first="Nils" last="Lycke">Nils Lycke</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435</s1>
<s2>40530 Götebors</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigen</term>
<term>Antigenic determinant</term>
<term>IgA</term>
<term>Immunological adjuvant</term>
<term>Immunomodulation</term>
<term>Influenza</term>
<term>Influenza A virus</term>
<term>Lymph node</term>
<term>Mucosa</term>
<term>Peptides</term>
<term>Spleen</term>
<term>Vaccination</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Muqueuse</term>
<term>Adjuvant immunologique</term>
<term>Vaccin</term>
<term>Vaccination</term>
<term>IgA</term>
<term>Immunomodulation</term>
<term>Rate</term>
<term>Ganglion lymphatique</term>
<term>Grippe</term>
<term>Antigène</term>
<term>Peptide</term>
<term>Déterminant antigénique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">At present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GRDIC ELIASSON (Dubravka)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>EL BAKKOURI (Karim)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SCHÖN (Karin)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RAMNE (Anna)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FESTJENS (Els)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LÖWENADLER (Bjdrn)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FIERS (Walter)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SAELENS (Xavier)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LYCKE (Nils)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Götebors, Box 435</s1>
<s2>40530 Götebors</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department for Molecular Biomedical Research, VIB and University of Ghent</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Biovitrum AB</s1>
<s2>Götebory</s2>
<s3>SWE</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>AstraZeneca</s1>
<s2>Götebors</s2>
<s3>SWE</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>1243-1252</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000175098950120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>63 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0158301</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>At present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Muqueuse</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mucosa</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Mucosa</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Adjuvant immunologique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Immunological adjuvant</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>IgA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>IgA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>IgA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Immunomodulation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Immunomodulation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Inmunomodulación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Rate</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Spleen</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Bazo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Ganglion lymphatique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Lymph node</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ganglio linfático</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Grippe</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Influenza</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Gripe</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Antigène</s0>
<s5>67</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Antigen</s0>
<s5>67</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Antígeno</s0>
<s5>67</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Peptide</s0>
<s5>68</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Peptides</s0>
<s5>68</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Péptido</s0>
<s5>68</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Déterminant antigénique</s0>
<s5>69</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Antigenic determinant</s0>
<s5>69</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Determinante antigénico</s0>
<s5>69</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>098</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000466 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000466 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:08-0158301
   |texte=   CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine

CTA1-M2e-DD : A novel mucosal adjuvant targeted influenza vaccine

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri